Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E7389 (Eribulin) in Advanced/Metastatic Breast Cancer
NCT00097721Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Sep 2004
- Primary completion
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eribulin in breast cancer, sponsored by Eisai Co., Ltd. Primary endpoint: Overall Response Rate. Started Sep 2004; status: completed.
02
Drugs
eribulin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00097721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00097721.